New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:05 EDTJAZZJazz Pharmaceuticals agrees to acquire rights to defibrotide in Americas
Jazz Pharmaceuticals announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals under which a subsidiary of Jazz Pharmaceuticals will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. As part of the agreement, Sigma-Tau would receive an upfront payment of $75M upon closing of the transaction. Sigma-Tau would be eligible to receive milestone payments of $25M upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and up to an additional $150M based on the timing of potential FDA approval of defibrotide for VOD. Jazz expects to fund the transaction with cash on hand and that the transaction will close during the third quarter of 2014, subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
09:08 EDTJAZZJazz Pharmaceuticals reports data from Phase 3 pivotal study of defibrotide
Jazz Pharmaceuticals announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the Journal of the American Society of Hematology, or ASH. The data demonstrated that defibrotide use in patients with hepatic veno-occlusive, or VOD, also known as sinusoidal obstruction syndrome, with multi-organ failure post-hematopoietic stem-cell transplantation was associated with a statistically significant improvement in Day +100 survival and in rate of complete response by Day +100, compared with rigorously selected historical controls.
January 29, 2016
06:55 EDTJAZZ2016 could be pivotal year for Jazz, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert says 2016 could be a pivotal year for Jazz Pharmaceuticals. The analyst sees several potential catalysts for the shares, including potentially greater certainty on Xyrem duration via a patent settlement or a win in court, FDA approval of defibrotide and acquisitions supported by the company's under-leveraged balance sheet. Gilbert keeps a Buy rating on Jazz with a $167 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use